IBIO
iBio, Inc.NASDAQHealthcare$1.98+2.53%ClosedMarket Cap: $31.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.56
P/S
106.84
EV/EBITDA
-0.27
DCF Value
$0.25
FCF Yield
-59.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-76.7%
Operating Margin
-7657.7%
Net Margin
-8245.7%
ROE
-71.3%
ROA
-38.4%
ROIC
-38.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $0.00 | -Infinity% | $-6.9M | $-9.0M | $-0.09 | — |
| Q1 2026 | $100.0K | -189.0% | $-6.0M | $-5.7M | $-0.11 | — |
| Q4 2025 | $200.0K | 100.0% | $-5.2M | $-5.2M | $-0.31 | — |
| FY 2025 | $400.0K | 100.0% | $-18.6M | $-18.4M | $-1.75 | — |
| Q3 2025 | $0.00 | NaN% | $-4.9M | $-4.9M | $-0.49 | — |
| Q2 2025 | $200.0K | 100.0% | $-4.4M | $-4.4M | $-0.48 | — |
| Q1 2025 | $0.00 | NaN% | $-4.1M | $-4.0M | $-0.46 | — |
| Q4 2024 | $175.0K | -60.6% | $-3.4M | $-7.8M | $-0.90 | — |
| FY 2024 | $225.0K | 100.0% | $-16.6M | $-24.9M | $-6.50 | — |
| Q3 2024 | $0.00 | NaN% | $-3.6M | $-3.2M | $-0.85 | — |
| Q2 2024 | $0.00 | NaN% | $-4.5M | $-8.2M | $-4.42 | — |
| Q1 2024 | $50.0K | -400.0% | $-5.1M | $-5.7M | $-4.79 | — |